Assessing the clinical utility of cancer genomic and proteomic data across tumor types. - Wikidata - awgldk - TriplyDB

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

http://www.wikidata.org/entity/Q30487077

about

The path to routine use of genomic biomarkers in the cancer clinic Identifying novel biomarkers through data mining-a realistic scenario?Training stem cells for treatment of malignant brain tumors The proteomic landscape of triple-negative breast cancer.Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.Technological considerations for genome-guided diagnosis and management of cancer Proteomics of ovarian cancer: functional insights and clinical applications Public data and open source tools for multi-assay genomic investigation of disease Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer NCC-AUC: an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data.Integration and comparison of different genomic data for outcome prediction in cancer.Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data.Assessing the clinical utility of genomic expression data across human cancers.Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Deep Profiling of Proteome and Phosphoproteome by Isobaric Labeling, Extensive Liquid Chromatography, and Mass Spectrometry.Cancer3D: understanding cancer mutations through protein structures.Identification of urine protein biomarkers with the potential for early detection of lung cancer.Subclonal diversification of primary breast cancer revealed by multiregion sequencing.The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma.In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model Identification of gene-drug interactions that impact patient survival in TCGA.Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.Revealing cancer subtypes with higher-order correlations applied to imaging and omics data NaviCom: a web application to create interactive molecular network portraits using multi-level omics data.Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach.Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.The prognostic landscape of genes and infiltrating immune cells across human cancers SURVIV for survival analysis of mRNA isoform variation.An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles.Protein Markers Predict Survival in Glioma Patients.Precision medicine for advanced prostate cancer.Importance of rare gene copy number alterations for personalized tumor characterization and survival analysis.A METHYLATION-TO-EXPRESSION FEATURE MODEL FOR GENERATING ACCURATE PROGNOSTIC RISK SCORES AND IDENTIFYING DISEASE TARGETS IN CLEAR CELL KIDNEY CANCER.iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes.Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.

P2860

Q26782733-06A2D93D-9541-4FCF-8F71-681E5AC1DFAF Q26995754-2B66E7E8-7E6C-4DD8-9863-F0E3E94CEF81 Q27006790-2631364C-67E1-49AB-B3C1-BDBF531D6B4E Q27320721-AD2AE045-3D25-4668-BC0C-FD4EFA34247D Q27853376-7B2F2BA3-0B31-4AF4-96C9-14D442C524AC Q28066706-B16ADEC0-7D68-4B8D-A376-EC4B318815D4 Q28082632-D3F442AE-9D48-4C65-B026-191D75C0D5D5 Q28596241-F20F915A-4A86-45A9-89E2-CC0205C9D2D9 Q30938412-3DA137F8-BFCC-4A38-8927-B474CF8481EC Q30975484-CCA45144-7AB9-4841-91B6-D8D4847644C4 Q31013326-28493021-4D16-4978-BAA4-EF7734D23E92 Q31028108-9182523E-91D5-4322-A27E-B2BB5C52FF40 Q31096420-7242CE01-F0D4-429D-993E-7B71C219688C Q31109151-D23B89C7-11B5-4960-A340-D662554B8B84 Q31134060-BCBF08C8-2E6F-4E17-89A8-F00DF427EC5B Q33719518-62A662A2-5601-47BC-B1E5-8D611D52A6AA Q35253926-B1EF9057-C08D-422B-8F54-6330B99B8A30 Q35809192-165948BF-2EC0-434C-A6E3-FD80B6310260 Q35847434-155FBFB2-CBC4-4633-A5B5-1B11954DE13C Q35895572-7BBF50A1-6697-4770-9435-955D3A88F1AA Q36001978-71C1E695-DF1F-4119-A05C-4F220911B597 Q36070506-B8416A72-EA0A-4D3D-8C39-36F0F550257E Q36140933-3E33D214-65EA-468F-AED1-EAF5B54E7545 Q36156355-5E7E7012-7CC3-4FAD-B4A7-1BD71E35660C Q36326276-A575A608-4E39-4A81-A192-C2052514339E Q36328777-C7EE7309-31F0-4EA6-9ED1-231937060675 Q36348691-D41252F4-409F-41DA-9EE2-2F0B5545C563 Q36471479-5790C48A-FB82-4FC5-B674-478C2A3C1676 Q36782423-5A9E3D12-DC64-40EF-BA55-E54D1129BDD7 Q36838932-7E48B3AA-628F-401F-878B-1AA43564C812 Q36857285-994B05DD-6703-4B9C-A380-EFA08984455F Q37000093-5D5C2DEC-DD93-4C04-81AD-9639FC70E60A Q37002648-8E9E6A83-39B0-43C3-B11C-4EE1577E1BB0 Q37076838-E11FFFA4-8D3D-494B-8552-4213FCD60593 Q37076888-CFED8EA7-3812-405D-B67F-9AD8E6F649A6 Q37114034-966BABF0-DC76-487A-A758-006A393E9863 Q37303817-99946C46-C7F4-4F93-B025-D67B96542EBF Q37526339-FAAE7417-2BF8-46DE-A90B-01B0A5DCFC02 Q37529618-3A7E4E5A-72E9-40F9-902E-44ACDA2E6B01 Q38605171-E68EC122-D353-4E61-81FC-90BED127C6FA

P2860

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

http://www.wikidata.org/entity/Q30487077

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@ast

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@en

type

label

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@ast

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@en

prefLabel

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@ast

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

@en

P1433

Q30487077-09832E37-42E2-46CB-8683-B7D37B1CDE47

P1476

Q30487077-823495EF-B680-4710-B018-746E509E7CBE

P2093

Q30487077-1A2AE27A-8B11-453E-B878-66C090B2F9FD

Q30487077-3AC4C2D8-61B1-4FC8-832D-0A9E73AA7842

Q30487077-458FF2B1-B4B7-4792-B7F3-267C4A20D724

Q30487077-54450CAA-E248-46E5-AB18-A1C25028C53C

Q30487077-68111C42-0D12-4AB4-AE4C-B0B4585E6643

Q30487077-7468348B-89F0-4E1A-9625-3B15750D1563

Q30487077-8823BF99-804A-4221-9C2B-0415BD4A9FA7

Q30487077-A30A423D-FFB5-4310-A6B7-5D0220F73E5A

Q30487077-B7A0E794-648B-46A2-9ADB-01342E75FECC

Q30487077-C080CD4C-F815-4047-812F-DE8DD70EFA67

P2860

Q30487077-00FEDB9E-E9AB-49A1-BF1A-A41E30520FB6

Q30487077-045DAD57-AE1C-4983-AF67-BE28A483CCD1

Q30487077-0AC9909C-DAFA-4512-BF2C-1FB0889B6E72

Q30487077-0D1C5BA8-13C0-4E62-AB0F-953632969962

Q30487077-10350845-E1CE-48B3-BCEB-09351CD1D6D1

Q30487077-21C2116A-A622-4668-925D-5BF1BFC37A56

Q30487077-220841F4-5CB2-49C7-8A59-CEDE6BAD74F6

Q30487077-239C507C-E5BA-4301-B759-1A6D2DC6CC58

Q30487077-297E1BF6-1F67-46E9-ABEF-185CCA7EEBCE

Q30487077-3446E559-2A48-436A-8948-1E23A9E0166F

P2888

Q30487077-CFB1308B-9657-4097-A46F-7C238556B32F

P304

Q30487077-96208AAA-1F19-481F-B274-2A12CC804AC2

P31

Q30487077-54585D00-6C51-45B8-BE3E-0B1771F192FB

P356

Q30487077-4C63B142-E848-4A5E-A3CD-8B5EFCC48F60

P433

Q30487077-10430D7E-19E7-4421-9D07-8515B372B250

P478

Q30487077-07DE870A-CF6C-4562-A8E3-C76F781537D0

P50

Q30487077-1DB0C4EF-9366-4AD8-92FE-96E3E85DABEB

Q30487077-38FF5E13-212E-4649-8CA7-C8597EBB0C67

Q30487077-435306F8-B860-499D-B7F7-5840ADD4ABAF

Q30487077-7ED39840-F128-409A-A4C8-DAFB6A8E6C9B

P577

Q30487077-A1ACC5B8-FBEE-4AF8-84EB-A8DC5A86AC46

P5875

Q30487077-8CF103D4-1D60-4F8B-91DD-0C6FAE142646

P698

Q30487077-D04509E5-CFCC-4752-8E67-D6E417C14879

P932

Q30487077-3BC78749-DC41-4A59-A7B7-2B3DDF585D60

P356

P1433

Nature Biotechnology

P1476

Assessing the clinical utility of cancer genomic and proteomic data across tumor types

@en

P2093

Adam A Margolin

http://www.w3.org/2001/XMLSchema#string

Ali Amin-Mansour

http://www.w3.org/2001/XMLSchema#string

Artem Sokolov

http://www.w3.org/2001/XMLSchema#string

Eliezer M Van Allen

http://www.w3.org/2001/XMLSchema#string

Gad Getz

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

John N Weinstein

http://www.w3.org/2001/XMLSchema#string

Josh M Stuart

http://www.w3.org/2001/XMLSchema#string

Kenneth R Hess

http://www.w3.org/2001/XMLSchema#string

Larsson Omberg

http://www.w3.org/2001/XMLSchema#string

P2860

Profiling critical cancer gene mutations in clinical tumor samples

Comprehensive molecular characterization of human colon and rectal cancer

Genome sequencing identifies a basis for everolimus sensitivity

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Integrated genomic analyses of ovarian carcinoma

Comprehensive genomic characterization of squamous cell lung cancers.

P2888

P304

644-652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.2940

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Levi A Garraway

P577

2014-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263296758

http://www.w3.org/2001/XMLSchema#string

P698

24952901

http://www.w3.org/2001/XMLSchema#string

P932

4102885

http://www.w3.org/2001/XMLSchema#string